United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Donald Trump's electoral victory has shaken the market, mostly in a good way.

Opinion: Pfizer (PFE) Stock Will Hit $22 Before It Hits $33 During Trump's Presidency

AbbVie

Gilead Sciences

High yields aren't a warning indicator with these three stocks.

3 Spectacular High-Yield Dividend Stocks to Buy in November

NIKE

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

2 Magnificent S&P 500 Dividend Stocks Down Year to Date to Buy and Hold Forever

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Pfizer presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Relative Strength Alert For Pfizer

PFE's core portfolio and strategic acquisitions continue to deliver decent results, no matter the lumpy sales contribution from Comirnaty and Paxlovid. The company raised their FY2024 core portfolio sales guidance, with the richer adj EPS numbers signaling the management's promising progress in cost and operational optimization. Even so, PFE continues to face massive patent cliff headwinds through 2030, with $31.58B of its annualized FQ3'24 revenues at stake.

Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

Allianz SE

Ares Capital

Bank of America

ING Groep NV

Johnson & Johnson

JPMorgan Chase & Co

LyondellBasell Industries

Altria

National Retail Properties

Realty Income Corp

Rio Tinto plc Sponsored

AT&T

Verizon

I will highlight 10 high dividend yield companies which, I believe, are worth considering investing in for November 2024. Each company could increase your portfolio's ability to generate dividend income due to having an elevated Dividend Yield. I believe that the selected companies can deliver investors sustainable dividend income, evidenced by their relatively low Payout Ratios and strong track record of dividend enhancements.

My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%

Best Buy

Conagra Brands

Equity Residential

Entergy

Federal Realty Investment Trust

KeyCorp

Kimco Realty

Kinder Morgan

Mid-America Apartment Communities

ONEOK

Regions Financial

Simon Property Group

Truist Financial

U.S. Bancorp

Williams

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” —Barron's Weekly. In an interview with Barron's, Steven Wieting, strategist at Citi Wealth, stated a growing dividend is a shareholder benefit and a hallmark of strong balance-sheets. “Nobody can fake a dividend,” he-said.

Buy 7 November Barron's Better Bet DiviDogs Of 23 & Watch 3 More To Be 'Safer'

UnitedHealth Group

One stock yields 6% today. Another has grown its dividend by 460% over the past decade.

2 Healthcare Dividend Stocks That Are Screaming Buys in November

Pfizer is trading above its 52-week low but is still a dirt cheap buy.

3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now

Coinbase

First Solar

iShares Russell 2000 ETF

Energy Select Sector SPDR Fund

Equities usually rise regardless of who assumes the White House. However, savvy, active investors understand the importance of analyzing specific industries under a new administration.

5 Industries to Watch in a Trump Administration

BioNTech SE

HCA Healthcare

Humana

Eli Lilly

Tenet Healthcare

Universal Health Services

Health Care Select Sector SPDR Fund

Investors are worried about what a Trump administration means for hospital operators and vaccine makers, but are optimistic about the fate of Medicare Advantage plan providers.

Why most healthcare stocks are falling with Trump's win, with some exceptions

Alibaba

Brinker International

Leidos Hld

Virtu Financial

Here are five stocks with a discounted PEG ratio, BABA, PFE, VIRT, LDOS and EAT, suitable for GARP investors.

5 PEG-Based GARP Stocks to Buy Amid Election Week Volatility

Peabody Energy

Greenbrier Companies

G-III Apparel Group

JAKKS Pacific

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, JAKK, GBX and PFE hold promise.

5 Low Price-to-Sales Stocks to Craft a Rewarding Investment Portfolio

News for Pfizer Stock (PFE)